The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first monobactam/β-lactamase inhibitor combination to be cleared in the US for ...

In February 2010, aztreonam for inhalation solution (Cayston; Gilead) — an inhalable formulation of the monobactam antibiotic aztreonam and lysine — was approved by the US FDA to improve ...